275 results about "Cyclic compound" patented technology

Disclosed is a liquid crystal composition. The liquid crystal composition includes liquid crystal molecules including at least one of a liquid crystal compound having an alkenyl group and a liquid crystal compound having an alkoxy group, and a first stabilizer including a compound having a structure represented by Formula 1:where n is 0 or 1; m is 0 or 1; k is 0 or 1; Z1, Z2, and Z3 are each independently a single bond, —C═C—, —OCO—, —COO—, —CF2O—, or a C1 to C5 alkylene group; X1, X2, X3, and X4 are each independently hydrogen or halogen; Y is hydrogen, an alkylene group, an alkoxy group, a hydroxyl group, —NHCOCH3, or ═O; and A and B are cyclic compounds.

The invention provides an imine covalent organic polymer and a preparation method thereof, a negative electrode material and a potassium ion battery. The preparation method comprises the following steps: carrying out first mixing on raw materials including a carbonyl-containing first organic compound, an amino-containing second organic compound and a dispersion liquid to obtain a mixed liquid; carrying out in-situ polymerization reaction on the mixed solution to obtain an imine covalent organic polymer; wherein the first organic compound is nitro-substituted or non-substituted pyrene-4, 5, 9, 10-tetraketone; the second organic compound is selected from any one or more of C6-C12 aromatic amine compounds, C6-C12 heteroaromatic amine compounds and amino-substituted C4-C6 cyclic compounds, and the number of amino groups in each molecule of the second organic compound is greater than or equal to 2. The covalent organic polymer obtained by the preparation method can solve the problem that the structure is easily stacked and is easily dissolved in electrolyte to be damaged when the covalent organic polymer is used as a negative electrode material.

A resist underlayer film, which, while exhibiting excellent resistance to a resist developer which is a resist solvent or an alkaline aqueous solution, exhibits removability, and preferably solubility, only in wet etching chemicals. This composition for forming a resist underlayer film contains a solvent, a heterocyclic compound having a dicyanostyryl group, a cyclic compound including an amide group, for example, and the reaction product of a heterocyclic compound precursor having an epoxy group and an active proton compound, for example.

The invention provides a cyclic compound with a structure as shown in a formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule of the cyclic compound, and a pharmaceutical composition and application of the cyclic compound or the pharmaceutically acceptable salt or the stereoisomer or the prodrug molecule of the cyclic compound. The compound can be used as a protein kinase inhibitor, has very strong inhibitory activity on FLT3 mutant kinase, has very strong proliferation inhibitory activity on Ba / F3-FLT3-ITD and stable strain cells containing drug-resistant point mutation, can inhibit proliferation, migration and invasion of various tumor cells, and especially can overcome the drug resistance of existing clinical drugs. The cyclic compound provided by the invention can be used for preparing medicines for preventing or treating FLT3 tyrosine kinase mediated diseases (such as hematological malignancies), and can be used for treating various hematological malignancies of human beings and other mammals. # imgabs0 #

An etchant composition includes hydrogen peroxide, a carboxylic acid-based compound, a fluorine-based compound, and a nitrogen-based cyclic compound. The hydrogen peroxide is included in an amount of 0.001 to 4 wt %. Additionally or alternatively, the weight ratio between the fluorine-based compound and the nitrogen-based cyclic compound is 1:0.01 to 1:3.

The present application relates to compounds of formula (I) as defined herein and pharmaceutically acceptable salts thereof. Also described are pharmaceutical compositions comprising the compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as methods of using the compounds and compositions for the treatment of diseases such as cancer, autoimmune disorders, and inflammatory disorders. # imgabs0 #

A compound represented by the following formula (1):wherein RG is a group containing at least one cyclic structure,I is an iodine atom,R1 is a monovalent functional group having 0 to 30 carbon atoms, containing no polymerizable unsaturated bond, and being optionally the same or different;n is an integer of 1 to 5, andm is an integer of 1 to 5.

The invention discloses a method for photocatalytic synthesis of N, O-spiroketal amine derivatives, and belongs to the technical field of organic synthesis. Aiming at the problems of harsh conditions, small substrate range and the like of the existing synthesis method, the invention provides the method for photocatalytic synthesis of the N, O-spiroketal amine derivative, and the method comprises the following steps: mixing a 1-alkenyloxy ring compound, a 1-azido vinyl ring compound, a photocatalyst, alkali and an organic solvent, and carrying out photocatalytic reaction to obtain the N, O-spiroketal amine derivative. The 1, 1, 2-trifunctional reaction of the N-alkenyloxy onium salt and the vinyl azide is successfully realized through a strategy of efficiently constructing an N, O-spiroketal amine skeleton under the catalysis of photooxidation reduction, and the method is simple and convenient to operate and high in yield. The method is mild in reaction condition, stable in process condition, high in product yield, easy in product purification, wide in substrate range, good in functional group tolerance, low in production cost and suitable for large-scale production.

[Problem] The present invention is to provide a photosensitive resin composition that makes it possible to form a cured film that can be used in a liquid crystal display element, an organic EL display element, an inorganic EL display element, or the like. The water and oil repellency of the surface of the cured film are to be maintained without loss through a development step, and a substrate is to be given high water and oil repellency such that an EL element formation ink achieves favorable spread without overflowing a bank to an adjacent pixel or causing cissing or unevenness. In other words, the present invention is to provide a photosensitive resin composition that makes it possible to form a cured film that has developer resistance, liquid repellency, and ink wettability. [Solution] A photosensitive resin composition according to the present invention contains components (A)–(D). (A) An alkali-soluble polymer. (B) A liquid-repellent polymer that includes a copolymer that comprises at least (B1) a monomer that includes a liquid-repellent group, (B2) a monomer that includes a trialkoxysilyl group, and (B3) a monomer of a cyclic compound. (C) A photosensitizer. (D) A solvent.

The invention discloses a synthesis method of 9-dichloromethylene-5-amino-benzonorbornene and an intermediate product, the synthesis method comprises the following steps: firstly, synthesizing a cyclization compound 1 as shown in a formula 1 from a cold solution of 6, 6-dichlorofulvene and 1, 4-benzoquinone under the action of a solution of a catalyst I, carrying out oximation reaction on the cyclization compound 1 prepared in the step a and hydroxylamine salt under an alkaline condition, and carrying out post-treatment to obtain the 9-dichloromethylene-5-amino-benzonorbornene. Under the action of a catalyst II, adding the oximate 2 prepared in the step b into a closed container, carrying out hydrogenation reduction to obtain 9-dichloromethylene-5-amino-benzo norbornene, and directly treating the reduction product with acid to obtain 9-dichloromethylene-5-amino-benzo norbornene, namely the 9-dichloromethylene-5-amino-benzo norbornene, namely the 9-dichloromethylene-5-amino-benzo norbornene. According to the method, the cyclization compound is oximated firstly, then the residual carbonyl and two double bonds on the ring are subjected to one-step reduction through catalytic hydrogenation, the working procedure is optimized, meanwhile, reduction by using expensive sodium borohydride is avoided, the method is short in synthesis route and suitable for industrialization, and the production cost is reduced.

The application provides a cyclic imide derivative with a high-efficiency multi-exciton effect and a synthesis method and application thereof, and belongs to the technical field of organic optoelectronic materials. The cyclic imide derivative has any one of the following structural formulae: wherein n is 1 or 2 or 3; m is an integer in 1-15; Ar represents an aryl group; and R is selected from a substituted or unsubstituted C1-C15 alkyl chain or a phenyl chain. The application directly synthesizes a novel cyclic compound through a synthesis method, and a series of different cyclic imide compounds can be further synthesized by changing the number of aryl groups on the ring and the type of imide compounds. Experimental tests prove that the cyclic imide compound can be applied in the field of singlet fission materials, and excellent bipolar transport performance is exhibited when the cyclic imide compound is applied in an organic field effect transistor device, so the cyclic imide compound has a good industrial application prospect.

To provide a substituted heterocyclic fused cyclic compound having a novel structure, which is used as a selective inhibitor for KRAS mutations and has the advantages of high activity, good selectivity, low toxicity and side effects, etc.SOLUTION: The present invention relates to a substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof to the preparation of cancer drugs.SELECTED DRAWING: None

The present disclosure relates generally to materials including cyclic compounds that are adhesive below the temperature at which pyrolysis occurs, and which are also adhesive at higher temperatures including the temperatures used in the regime for growing SiC crystals, which may be above 2000° C, or for SiC or GaN epitaxy, which may be above 1500° C.

The application discloses a synthesis method of aza-cyclic modified hydroxyalkyl diethanolamine borate linking agent, which comprises the following steps: (1) adding hydroxyalkyl diethanolamine and boric acid into a three-neck flask provided with a stirrer, a thermometer and a vacuum distillation device, and stirring and heating to react until no water is generated; (2) adding an aza-cyclic compound into the reaction system obtained in the step (1), increasing the reaction temperature, and removing water generated in the reaction by vacuum distillation when no water vapor is generated, so as to obtain a target product. The borate linking agent obtained by the synthesis method has good hydrolysis resistance, and when the borate linking agent is used in a hydroxyl-terminated solid propellant, the mechanical properties of the hydroxyl-terminated solid propellant can be effectively improved.

A compound represented by formula (I). The compound has good agonistic activity on an APJ receptor, can effectively inhibit the production of cAMP, has weak ability to recruit β-arrestin, and has good pharmacokinetic properties.

Disclosed are a composition for removing edge beads from a metal-containing resist or a metal-containing resist developer composition, and a method of forming or providing a pattern using the composition or the developer composition. The composition for removing edge beads from a metal-containing resist or the developer composition of a metal-containing resist may include: a cyclic compound including in a ring at least one heteroatom selected from N, O, and S and at least two carbonyl groups; and a solvent.

The invention discloses a lithium ion battery electrolyte based on a chalcogenide cyclic compound, a preparation method of the lithium ion battery electrolyte and a ternary lithium ion battery. The lithium ion battery electrolyte comprises an organic solvent system, a lithium salt system and an additive system, the organic solvent system comprises at least one cyclic carbonate and at least one chain carbonate; the additive system comprises a chalcogenide cyclic compound, and the chalcogenide cyclic compound has the following structural formula; an X group is selected from any one of the following groups; wherein the Y group, the Y1 group and the Y2 group are respectively and independently selected from any one of halogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, silicon group and carboxyl; according to the invention, the cycle life of the ternary lithium ion battery can be effectively prolonged, the cycle performance of the ternary lithium ion battery (especially an NCM622 ternary lithium ion battery) can be obviously enhanced, and the service life of the ternary lithium ion battery can be obviously prolonged.

A drug delivery system delivers a cyclic compound to a target cell or tissue while suppressing the pharmacological activity of the cyclic compound. A complex includes the cyclic compound and a delivery carrier having a shaft portion for carrying the cyclic compound. The shaft portion is complexed by inclusion in the cyclic compound to form a host-guest complex.

A curable resin composition includes (A) a specific curable resin and (C) a curing agent, and further includes (BI) 0.1 parts by mass or more and 20 parts by mass or less of a polyhydric alcohol having 2 to 5 hydroxyl groups, based on based on 100 parts by mass of the curable resin (A); (BII) a cyclic compound having 3 to 6 reactive groups and a reactive group equivalent of 100 g / eq or more and 300 g / eq or less; or (BIII) a specific oxetane compound in a mass ratio of the curable resin (A) to the oxetane compound (BIII) being 5:5 to 9:1.

The invention provides an electrolyte, a battery, a battery pack and electric equipment. The electrolyte comprises a cyclic sulfite compound as shown in a formula 1 and / or a cyano phosphate cyclic compound as shown in a formula 2. According to the solvent provided by the invention, the total entropy value of an electrolyte can be increased, the solvation structure of lithium ions can be adjusted, and side reactions are reduced by inducing film formation on an electrode interface, so that the cycle stability and the storage life of a battery at a high temperature and the charging efficiency at a low temperature can be improved.

The invention discloses an electrolyte of a ternary lithium ion battery, a preparation method of the electrolyte and the ternary lithium ion battery. The ternary lithium ion battery comprises an organic solvent system, a lithium salt system and an additive system, the organic solvent system is composed of at least one cyclic carbonate and at least one chain carbonate; the additive system comprises a cyclic compound, and the cyclic compound has the following structural formula; wherein X is any one of P, B and P = O; y is a C1-C6 carbon chain group containing an alkylene group, a carbonyl group, a sulfinyl group, a sulfonyl group or a fluoroalkylene group; the flame-retardant and anti-overcharge fabric has flame-retardant and anti-overcharge And moreover, by regulating and controlling the composition of the SEI film, the growth of lithium dendrites can be inhibited, the dissolution of transition metal can be reduced, the stability of the ternary lithium ion positive electrode material is improved, and the cycle life of the ternary lithium ion battery is prolonged.

Provided is a novel photothermal conversion material. A manganese oxide cluster compound represented by general formula (1). (In general formula (1), L is a tricarboxytriptycene residue, alpha1 is an organic acid residue, beta1 is a solvent selected from the group consisting of water and a polar organic solvent having a dielectric constant of 6-47, P1 is a coordinating molecule selected from the group consisting of a nitrogen-containing heterocyclic compound, an oxygen-containing cyclic compound and a phosphine, or a polymer containing the coordinating molecule, [gamma] 1 is a solvent selected from water and a polar organic solvent having a dielectric constant of 6-47, q is a number of 0 < = m < = 8, and m is a number of 0 < = m < = 10. ).

Provided is an etchant composition including, about 3.0 wt % to about 15.0 wt % of ammonium persulfate, about 0.1 wt % to about 5.0 wt % of an inorganic acid, about 0.1 wt % to about 2.0 wt % of a fluorine-containing ammonium salt, about 0.01 wt % to about 1.5 wt % of a chlorine-containing ammonium salt, about 0.1 wt % to about 2.0 wt % of a 2-nitrogen cyclic compound, about 0.1 wt % to about 2.0 wt % of a 4-nitrogen cyclic compound, about 0.1 wt % to about 3.0 wt % of an aminosulfonic acid, and a remainder of water such that the total weight of the entire etchant composition becomes 100 wt %, wherein the weight ratio of the 4-nitrogen cyclic compound to the 2-nitrogen cyclic compound is in a range of about 1.6 to about 5.0.

A condensed cyclic compound represented by Formula 1, a light-emitting device including the condensed cyclic compound, and an electronic apparatus including the light-emitting device:wherein Formula 1 is as described herein.

Provided are a condensed cyclic compound represented by Formula 1, an organic light-emitting device including the condensed cyclic compound represented by Formula 1, and an electronic apparatus, wherein the description of substituents of Formula 1 are as described herein.

The present disclosure relates to a heterogeneous nuclear ribosomal protein A2B1(hnRNPA2B1)hnRNPA2B1 agonist compound and an anti-tumor use thereof. Specifically, the present disclosure relates to a condensed cyclic compound as represented by formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate or a pharmaceutically acceptable salt thereof or a prodrug thereof, a composition and product comprising any one of the foregoing, and a use of the described substances as an hnRNPA2B1 agonist in the preparation of a product for tumor prevention and / or treatment. The present disclosure can be used for broad-spectrum tumor prevention and treatment, and has a wide application prospect.

The invention discloses a cyclic compound serving as a multi-target kinase inhibitor and a preparation method of the cyclic compound. The multi-target kinase inhibitor disclosed by the invention is shown in a general formula I, and R1, R2, R3, R3a, L1, L2, L3, ring A and ring B are shown in the description and claims. The invention also discloses a preparation method of the general formula I and an activity inhibition test result of the general formula I for inhibiting various kinases. The compound as shown in the general formula I can be used for preparing medicines for treating neurodegenerative diseases such as cancer and Parkinson's disease. # imgabs0 #

A condensed cyclic compound and an organic light-emitting device including the same.

Disclosed is an etching liquid composition having excellent etching performance. According to one aspect, there is provided an etching liquid composition comprising: hydrogen peroxide; a phosphate; an amine having at least one or more hydroxyl groups; a fluoride; a tetraazacyclic compound having four nitrogen atoms within the ring; and a triazacyclic compound having three nitrogen atoms within the ring, and the weight ratio of the tetraazacyclic compound to the triazacyclic compound is 1:0.01 or more to 1:1.25 or less.